Alkermes Posts Strong 3Q Sales Uptick for VIVITROL PDF   E-mail
Addiction Treatment Industry Newswire
10/25/2018 -ATIN- Sales of pharma Alkermes' MAT therapeutic intervention VIVITROL jumped 15% in the third quarter to almost $80M, with Dublin-based Alkermes predicting that full year 2018 sales of the anti-craving med would reach a range of between $300M and $330M.

VIVITROL is clearly benefiting from the strenuous efforts of health insurers and public health policy makers to find solutions to the addiction epidemic, which has finally gained centerstage in the national healthcare debate in the wake of blanket media coverage around opiate use disorder. President Trump just this week signed a batch of bills that will unleash $8B in federal funding to fight drug addiction, of which MAT therapeutic interventions like VIVITROL will be substantial beneficiaries.

There are only a tiny handful of MAT interventions for addiction. VIVITROL is among the most prominent of these, but is far behind the blockbuster billion dollar buprenorphine compound of which Suboxone is the best recognized brand. VIVITROL is a monthly injection of the naltrexone compound, a drug that has been available in very cheap generic form for decades.

Alkermes launched VIVITROL to great fanfare over a decade ago, forming a marketing partnership with Cephalon, now part of pharma giant TEVA Pharmaceuticals. For years Alkermes had trouble pushing annual sales of VIVITROL past $20M, despite spending heavily on marketing.

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Comments (0)Add Comment

Write comment
smaller | bigger


Recent Print Issue: Sept 2015 | Subscribe Now!

Special Report
Austin's MAP Looking to Future
andValue-Based Compensation
Growth Through Licensing

On the Cover: Jacob Levinson
Founder, CEO MAP

Click here to read the digital
print edition of TM.

Follow Treatment Magazine on Twitter!
Become a fan of Treatment Magazine on Facebook!